Biotech Startups

Wespran develops biotechnology that converts industrial CO2 emissions into valuable chemicals like green methanol using engineered enzymes, serving heavy industries such as refineries and steel plants. The French startup operates a Decarbonization as a Service model to help industrial facilities reduce emissions while generating new revenue.

1 investor

Whelix manufactures autonomous cell-culture systems for research and production, including Associan™, a workcell combining AI-powered liquid handling with integrated incubation and automation for large-scale cell expansion and parallel processing.

1 investor

Whitehawk Therapeutics develops antibody-drug conjugate (ADC) therapeutics through intentional clinical development. The company brings expertise in biotech R&D and commercialization to treat patients using its ADC platform.

1 investor

Microbiome analysis company using lab science and machine learning to identify markers and interventions.

1 investor

Weinnovate Biosolutions develops antimicrobial treatments and infection prevention and control solutions for healthcare providers. The company focuses on reducing hospital-acquired infections and associated hospitalization costs.

1 investor

WildTechDNA develops a field-ready, instrument-free DNA detection technology based on isothermal DNA amplification, delivering same-day results without laboratory infrastructure. The single-kit system is applied across biodiversity monitoring and conservation, infectious disease and antimicrobial resistance diagnostics, wildlife and border enforcement, and pathogen detection in aquaculture and food systems.

1 investor

Wilk is a bio-foodtech company developing cell-cultured milk fat and dairy products, including a hybrid cell-based yogurt made without reliance on animals. It operates in the cultured dairy and cellular agriculture segment of the food industry.

1 investor

WindMIL Therapeutics is a clinical-stage biotechnology company developing cell-based immuno-oncology therapies using marrow-infiltrating lymphocytes (MILs), T cells extracted from a cancer patient's bone marrow that are activated and expanded before being returned to the patient. The company has exclusively licensed the underlying patents and know-how for MILs therapy from Johns Hopkins University.

1 investor

Window Therapeutics is a biotechnology company developing therapeutics for cancer and other life-threatening diseases, based on its bottle-brush-analogue-macromonomer (BAM) technology. The company applies molecular chemistry and biology research, originally developed in the MIT laboratory of Dr. Jeremiah Johnson.

1 investor

Wishbone develops W-Bone, a bovine-derived regenerative bone graft material for dental bone graft surgery and implant procedures. The product uses a patented manufacturing process designed to preserve the natural bone structure and support osseointegration for dental clinicians.

1 investor

Woodstock Sterile Solutions is a contract development and manufacturing organization (CDMO) specializing in aseptic pharmaceutical manufacturing of sterile liquid formulations using blow-fill-seal (BFS) technology. It serves healthcare and pharmaceutical companies, supporting products from clinical development through commercial-scale production, including biologics and temperature-sensitive drug products.

1 investor

A contract discovery services provider that generates, engineers, evaluates, and optimizes antibody drug conjugates (ADCs) and bioconjugates to help clients identify lead drug candidates. It serves pharmaceutical and biotech companies pursuing bioconjugate drug discovery.

1 investor

X-Imaging develops laboratory automation systems and collaborative robots for applied chemistry, life sciences, and microbiology research, serving pharmaceutical, biotechnology, and material science laboratories.

1 investor

X-ZELL develops a platform technology for isolating and visualizing rare and abnormal cells, such as Circulating Endothelial Cells, to enable early cancer detection from blood. Its four-module system covers blood processing through cell analysis and reporting for applications spanning research, medication management, companion diagnostics, relapse control, and diagnostic decision-making.

1 investor

Xap Therapeutics uses genome editing and synthetic biology to engineer a programmable cell-based delivery platform that carries therapeutic payloads such as cytokines, antibodies, and nucleic acids, releasing them upon target recognition. It is developing multi-modal therapies for complex diseases including cancer and autoimmunity.

1 investor

Xellia manufactures anti-infective pharmaceutical products with a focus on supply chain continuity and reliable availability of critical active pharmaceutical ingredients in Western markets.

1 investor

XenImmune is an immuno-oncology company developing first-in-class molecules that apply the biology of organ transplant hyperacute rejection to fight cancer by "painting" tumors with foreign blood groups to trigger anti-tumor immune responses. Its lead therapy has shown proof of concept in common tumor types in in vitro and in vivo settings.

1 investor

Xenter develops wireless medical technologies and a medical intelligence platform that aggregates devices, medical data, and diagnostics to apply AI in medicine, with expertise in medical devices and interventional cardiology. The company operates from Salt Lake City with a global network.

1 investor

1 investor

XGEN Venture is an Italian alternative investment fund manager (SGR) that makes early-stage investments in private life science research and development companies. It focuses on startups developing novel solutions for high unmet medical needs and is investing through its XGEN Venture Life Science fund.

1 investor

Crosslink Therapeutics develops protein engineering and cancer therapies, focusing on immunological and oncology treatments in the biopharmaceutical sector.

1 investor

XM Therapeutics develops extracellular matrix-based therapies to treat patients with chronic disorders, with initial applications targeting heart failure and pulmonary fibrosis. The company is based in Providence, Rhode Island and leverages partnerships with Brown University for research and development.

1 investor

1 investor

A biotechnology company developing a peptide-based delivery platform that uses lipid raft targeting to transport therapeutic proteins into the cytosol of human cells with minimal lysosomal degradation. The technology is designed for pharmaceutical companies and researchers needing intracellular delivery of therapeutic macromolecules.

1 investor